Literature DB >> 20061095

On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Ronald J Tallarida1, Alan Cowan, Robert B Raffa.   

Abstract

Buprenorphine, like many other drugs, displays a biphasic dose-response relation ('hormesis'), viz., its antinociceptive effect in some preclinical models increases up to some dose level (often achieving 100% effect) and decreases at high-doses. A decreasing component was evident in the tail-flick tests described here, occurring in both the mouse and the rat. While the mechanism of dose-related decline in antinociceptive effect, when observed, might be related to nociceptin/orphanin-FQ, the precise mechanism remains unknown. Regardless of the mechanism, the values of this dose-related decline yield data that can be used to calculate the dose-effect relation of the decreasing (unknown second) component. The calculation, which uses the same concept of dose equivalence that underlies additivity in isobolographic analysis, was employed here from tail-flick data obtained in mouse and rat. The derived dose-effect curves of the second component, though differing in efficacy between mouse and rat, displayed a very notable similarity. This novel technique offers possible insight into the dual low-dose (analgesic), high-dose (addiction medication) uses of buprenorphine. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061095      PMCID: PMC3996554          DOI: 10.1016/j.drugalcdep.2009.12.014

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  14 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

Review 2.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

3.  Characterization of nociceptin hyperalgesia and allodynia in conscious mice.

Authors:  N Hara; T Minami; E Okuda-Ashitaka; T Sugimoto; M Sakai; M Onaka; H Mori; T Imanishi; K Shingu; S Ito
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

4.  Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain.

Authors:  Thomas Christoph; Babette Kögel; Klaus Schiene; Murielle Méen; Jean De Vry; Elmar Friderichs
Journal:  Eur J Pharmacol       Date:  2004-12-30       Impact factor: 4.432

Review 5.  Buprenorphine for the treatment of opioid dependence.

Authors:  Lisa A Boothby; Paul L Doering
Journal:  Am J Health Syst Pharm       Date:  2007-02-01       Impact factor: 2.637

6.  Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain.

Authors:  F Benedetti; S Vighetti; M Amanzio; C Casadio; A Oliaro; B Bergamasco; G Maggi
Journal:  Pain       Date:  1998-02       Impact factor: 6.961

Review 7.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

8.  Buprenorphine: high-affinity binding to dorsal spinal cord.

Authors:  J W Villiger; K M Taylor
Journal:  J Neurochem       Date:  1982-06       Impact factor: 5.372

9.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  6 in total

Review 1.  Revisiting the isobole and related quantitative methods for assessing drug synergism.

Authors:  Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2012-04-17       Impact factor: 4.030

2.  Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition.

Authors:  Neil S Lamarre; Robert B Raffa; Ronald J Tallarida
Journal:  Drug Alcohol Depend       Date:  2012-12-25       Impact factor: 4.492

3.  Nicotine-induced C-shape movements in planarians are reduced by antinociceptive drugs: Implications for pain in planarian paroxysm etiology?

Authors:  Anthony Kim; Scott M Rawls
Journal:  Brain Res       Date:  2021-12-31       Impact factor: 3.252

4.  Thermal latency studies in opiate-treated mice.

Authors:  Noam Schildhaus; Eliana Trink; Chirs Polson; Louis Detolla; Betty M Tyler; George I Jallo; Sino Tok; Michael Guarnieri
Journal:  J Pharm Bioallied Sci       Date:  2014-01

5.  Critical illness induces nutrient-independent adipogenesis and accumulation of alternatively activated tissue macrophages.

Authors:  Mirna Marques; Sarah Perre; Annelies Aertgeerts; Sarah Derde; Fabian Güiza; Michael P Casaer; Greet Hermans; Greet Van den Berghe; Lies Langouche
Journal:  Crit Care       Date:  2013-09-10       Impact factor: 9.097

6.  Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'.

Authors:  Robert B Raffa; Christian Elling; Thomas M Tzschentke
Journal:  Adv Ther       Date:  2018-09-11       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.